"Analysis.group","Analysis.number","Analysis.name","Subgroup","Subgroup.number","Applicability","Study","Study.year","GIV.Mean","GIV.SE","Experimental.mean","Experimental.SD","Experimental.cases","Experimental.N","Control.mean","Control.SD","Control.cases","Control.N","O.E","Variance","Weight","Mean","CI.start","CI.end","Footnotes","Bias.arising.from.the.randomization.process.judgement","Bias.arising.from.the.randomization.process.support","Bias.due.to.deviations.from.intended.interventions.judgement","Bias.due.to.deviations.from.intended.interventions.support","Bias.due.to.missing.outcome.data.judgement","Bias.due.to.missing.outcome.data.support","Bias.in.measurement.of.the.outcome.judgement","Bias.in.measurement.of.the.outcome.support","Bias.in.selection.of.the.reported.result.judgement","Bias.in.selection.of.the.reported.result.support","Overall.bias.judgement","Overall.bias.support","review.url","review.doi","analysis_key","dataset_name","mismatch_type","direction_match","or_sig","rd_sig","log_or","rd","log_or_ci_lb","log_or_ci_ub","rd_ci_lb","rd_ci_ub","sparse_events","double_zero"
1,5,"Ulcer complications ","",NA,"SUBGROUP_AND_OVERALL","Chan 2007",2007,0,0,0,0,0,137,0,0,12,136,0,0,15.436846,0.03971,0.002375,0.664082,"","Some concerns","<p>The randomization process is well-detailed; however, in Table 1, some categories appear unbalanced. For example: Other Types of Arthritis: Esomeprazole 19 (14%) Placebo 12 (9%)</p>","Low risk","<p>The authors report that the study was a double-blind, placebo-matching study, and its analysis was appropriate as the authors performed an intention-to-treat analysis.</p>","Low risk","<p>An intention-to-treat analysis was conducted on all randomized patients, and data are available for all randomized participants</p>","Low risk","<p>The methodology for assessing the outcome variable was appropriate and was performed consistently in both groups.</p>","Low risk","<p>The analysis was prespecified in the study protocol, and intention-to-treat analysis was performed. Lost data was also declared.</p>","Low risk","<p>The study is judged to be at low risk of bias for this result</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014585.pub2/full","10.1002/14651858.CD014585.pub2","5::overall","CD014585_pub2_data","significance_only",TRUE,TRUE,FALSE,-1.0154411743203,-0.00294011011080847,-2.02790957629268,-0.00297277234791715,-0.00675272789016881,0.000872507668551864,TRUE,TRUE
1,5,"Ulcer complications ","",NA,"SUBGROUP_AND_OVERALL","Ekström 1996",1996,0,0,0,0,0,85,0,0,0,90,0,0,NA,NA,NA,NA,"","High risk","<p>The only information about randomisation is the statement that the study is randomised. There were imbalances between study groups.</p>","Some concerns","<p>The study follows a double-blind approach. A small number of participants were excluded post-randomisation but it was judged to not affect the results.</p>","Low risk","<p>Information for this outcome was available for all study participants.&nbsp;</p>","Low risk","<p>The outcome measure was the same in both groups.</p>","High risk","<p>Study protocol not available. The study methods section reports assessing outcomes at 1 and 3 months but the results section only reports at 3 months. The statistical analysis section provides insight into how the data for this outcome was treated and conducted.&nbsp;</p>","High risk","<p>The study is judged to be at high risk of bias for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014585.pub2/full","10.1002/14651858.CD014585.pub2","5::overall","CD014585_pub2_data","significance_only",TRUE,TRUE,FALSE,-1.0154411743203,-0.00294011011080847,-2.02790957629268,-0.00297277234791715,-0.00675272789016881,0.000872507668551864,TRUE,TRUE
1,5,"Ulcer complications ","",NA,"SUBGROUP_AND_OVERALL","Scheiman 2010",2007,0,1.54859380807221,0,0,2,1621,0,0,3,805,0,2.39814278239957,32.911988,0.331071,0.055431,1.977386,"Combined esomeprazole 20 mg and 40 mg.","Low risk","<p>A random component was used in the sequence generation process, and there were no imbalances between groups.</p>","Low risk","<p>This was a randomized quadruple-blind study, and its analysis was appropiate.&nbsp;</p>","Low risk","<p>There was a large amount of missing data, however, the result was probably not biased by missing data.&nbsp;</p>","Low risk","<p>The method of measuring the outcome was appropriate, the ascertainment was the same for the two groups.</p>","High risk","<p>Authors did not did not consider this outcome in their clinical trials registry, and it was reported only for the 26-week.&nbsp;</p>","High risk","<p>The study is judged to be at high risk of bias for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014585.pub2/full","10.1002/14651858.CD014585.pub2","5::overall","CD014585_pub2_data","significance_only",TRUE,TRUE,FALSE,-1.0154411743203,-0.00294011011080847,-2.02790957629268,-0.00297277234791715,-0.00675272789016881,0.000872507668551864,TRUE,TRUE
1,5,"Ulcer complications ","",NA,"SUBGROUP_AND_OVERALL","Whellan 2014",2014,0,0,0,0,1,264,0,0,1,265,0,0,15.937569,1.003788,0.063116,15.96412,"From Study 301.","Some concerns","<p>While the method of randomisation and allocation were not reported, we found no reason to suspect that biases were introduced at this point.</p>","Some concerns","<p>The study reports following a double blind apporach. Appropiate analyses was used.&nbsp;</p>","Low risk","<p>The number of participants who informed this outcome was similar to those who reached follow-up evaluations.</p>","Low risk","<p>Appropriate method for outcome assessment and consistent across groups.</p>","Low risk","<p>Gastric ulcer haemorrhage is reported as a serious adverse event. Gastric ulcer haemorrhage is reported as a serious adverse event through 6 months. Statistical analysis was performed according to pre-established methods / Reported results correspond to intended analysis</p>","Some concerns","<p>The study is judged to raise some concerns for this result because of issues related to the randomisation process.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014585.pub2/full","10.1002/14651858.CD014585.pub2","5::overall","CD014585_pub2_data","significance_only",TRUE,TRUE,FALSE,-1.0154411743203,-0.00294011011080847,-2.02790957629268,-0.00297277234791715,-0.00675272789016881,0.000872507668551864,TRUE,TRUE
1,5,"Ulcer complications ","",NA,"SUBGROUP_AND_OVERALL","Yeomans 2008",2008,0,0,0,0,2,493,0,0,4,498,0,0,35.713597,0.505071,0.092934,2.744911,"","Low risk","<p>A random component was used in the sequence generation process and there were no imbalances between groups.</p>","Low risk","<p>This was a randomized double-blind study, and the analysis seemed appropriate.</p>","Low risk","<p>There was a large amount of missing data, however, the result was probably not biased by missing data.</p>","Low risk","<p>The method of measuring the outcome was appropriate and was the same for the two groups.</p>","High risk","<p>Authors did not consider this outcome in their clinical trials registry and there is no information about the time point measured.&nbsp;</p>","High risk","<p>The study is judged to be at high risk of bias for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014585.pub2/full","10.1002/14651858.CD014585.pub2","5::overall","CD014585_pub2_data","significance_only",TRUE,TRUE,FALSE,-1.0154411743203,-0.00294011011080847,-2.02790957629268,-0.00297277234791715,-0.00675272789016881,0.000872507668551864,TRUE,TRUE
5,3,"Adverse events","Omeprazole",4,"SUBGROUP_AND_OVERALL","Cullen 1998",1998,0,0.392197246667963,0,0,19,83,0,0,8,85,0,0.153818680293931,0,2.432229,1.127627,5.246182,"","Some concerns","<p>It was a randomized double-blind, placebo-controlled, parallel-group study comparing omeprazole 20 mg o.m. with a placebo, given for up to 6 months. Table 1.&nbsp;</p>","Some concerns","<p>It was a randomised double-blind, placebo-controlled, parallel-group study comparing omeprazole 20 mg o.m. with placebo, given for up to 6 months. The study followed a double-blind approach, Inappropiat analyses were used for estimating the effects of the assessment on the intervention.&nbsp;</p>","Low risk","<p>Data available for nearly all participants were randomised.&nbsp;</p>","Low risk","<p>The method for outcome assessment was probably the same for both groups and consistent across groups.</p>","Some concerns","<p>No pre-specified analysis plan or protocol is available. No information about outcome measurement definitions. There were no multiple analyses for this outcome.</p>","Some concerns","<p>The study is judged to raise some concerns for this result because of issues related to the selection of the reported result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014585.pub2/full","10.1002/14651858.CD014585.pub2","3::4","CD014585_pub2_data","direction_only",FALSE,FALSE,FALSE,0.0172930436878386,-0.0191899722451864,-1.38559810260862,1.4201841899843,-0.148663947327187,0.110284002836814,FALSE,FALSE
5,3,"Adverse events","Omeprazole",4,"SUBGROUP_AND_OVERALL","Ekström 1996",1996,0,1.06948157986625,0,0,6,85,0,0,1,90,0,1.1437908496732,0,6.352941,0.780963,51.679607,"","High risk","<p>The only information about randomisation is the statement that the study is randomised. There were imbalances between study groups.</p>","Some concerns","<p>The study follows a double-blind approach. A small number of participants were excluded post-randomisation but it was judged to not affect the results.</p>","Low risk","<p>Information for this outcome was available for all study participants.&nbsp;</p>","Low risk","<p>The outcome measure was the same in both groups.</p>","High risk","<p>Study protocol not available. The study methods section reports assessing outcomes at 1 and 3 months but the results section only reports at 3 months. The statistical analysis section provides insight into how the data for this outcome was treated and conducted.&nbsp;</p>","High risk","<p>The study is judged to be at high risk of bias for this result</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014585.pub2/full","10.1002/14651858.CD014585.pub2","3::4","CD014585_pub2_data","direction_only",FALSE,FALSE,FALSE,0.0172930436878386,-0.0191899722451864,-1.38559810260862,1.4201841899843,-0.148663947327187,0.110284002836814,FALSE,FALSE
5,3,"Adverse events","Omeprazole",4,"SUBGROUP_AND_OVERALL","Whellan 2014",2014,0,0.0360792495123318,0,0,207,264,0,0,248,265,0,0.001301712245373,0,0.837839,0.780638,0.899231,"Data from Study 301","Some concerns","<p>While the method of randomisation and allocation were not reported, we found no reason to suspect that biases were introduced at this point.</p>","Low risk","<p>The study reports following a double-blind approach. Appropriate analyses were used.&nbsp;</p>","Low risk","<p>The number of participants that informed this outcome was similar to the intention to treat patients</p>","Low risk","<p>Appropriate method for outcome assessment and consistency across groups.</p>","Low risk","<p>No pre-specified analysis is reported; however 'Two independent adjudication committees blinded to study treatment evaluated all investigator reported serious CV events and potential UGI events based on reported symptoms, laboratory values, and/or endoscopic findings found at scheduled or for-cause evaluations and endoscopies'. All types of AE were reported / through 6 months plus 28 days for Serious Adverse Events and Randomization through 6 months for all non-serious adverse events.</p>","Some concerns","<p>The study is judged to raise some concerns for this result because of issues related to the randomisation process.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014585.pub2/full","10.1002/14651858.CD014585.pub2","3::4","CD014585_pub2_data","direction_only",FALSE,FALSE,FALSE,0.0172930436878386,-0.0191899722451864,-1.38559810260862,1.4201841899843,-0.148663947327187,0.110284002836814,FALSE,FALSE
5,3,"Adverse events","Omeprazole",4,"SUBGROUP_AND_OVERALL","Whellan 2014",2014,0,0.0415117979242714,0,0,198,257,0,0,226,259,0,0.0017232293669055,0,0.882924,0.813933,0.957764,"Data from Study 302","Some concerns","<p>While the method of randomisation and allocation were not reported, we found no reason to suspect that biases were introduced at this point.</p>","Low risk","<p>The study reports following a double-blind approach. Appropriate analyses were used.&nbsp;</p>","Low risk","<p>The number of participants that informed this outcome was similar to the intention to treat patients</p>","Low risk","<p>Appropriate method for outcome assessment and consistency across groups.</p>","Low risk","<p>No pre-specified analysis is reported; however 'Two independent adjudication committees blinded to study treatment evaluated all investigator reported serious CV events and potential UGI events based on reported symptoms, laboratory values, and/or endoscopic findings found at scheduled or for-cause evaluations and endoscopies'. All types of AE were reported / through 6 months plus 28 days for Serious Adverse Events and Randomization through 6 months for all non-serious adverse events.</p>","Some concerns","<p>The study is judged to raise some concerns for this result because of issues related to the randomisation process.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014585.pub2/full","10.1002/14651858.CD014585.pub2","3::4","CD014585_pub2_data","direction_only",FALSE,FALSE,FALSE,0.0172930436878386,-0.0191899722451864,-1.38559810260862,1.4201841899843,-0.148663947327187,0.110284002836814,FALSE,FALSE
